

COMPANY ANNOUNCEMENT

Hepatitis E rapid diagnostic tests shipped to WHO

8 September 2004, Melbourne, Australia: Select Vaccines Ltd. (ASX:SLT) is pleased to advise that Hepatitis E rapid diagnostic kits manufactured using technology developed by the Company have been shipped to the World Health Organisation (WHO) for use in the Darfur region of Sudan. Select Vaccines' Hepatitis E diagnostic technology was recently out-licensed to Genelabs Diagnostics Pte. Ltd. under a 12 year commercial contract.

Following receipt by Select Vaccines of a request from the WHO to supply Hepatitis E diagnostic kits and other forms of Hepatitis tests for use in Sudan and Iraq, the Company's licence partner for this product, Genelabs Diagnostics, has shipped a significant quantity of Hepatitis E rapid assay kits to the WHO. These have been provided on a humanitarian basis.

The request from the WHO was made following an outbreak of Hepatitis E infection within the refugee camps in the Darfur region. The outbreak has affected several hundred people and has caused at least twenty deaths according to recent press reports. The conditions within these camps are such that an outbreak of Hepatitis E infections is not surprising and is likely to spread rapidly. The WHO will use the test kits to help contain the spread of the disease and manage those people who have been infected.

About Select Vaccines Limited

Select Vaccines listed on the ASX on 3 July 2003. It is in partnership with Melbourne's Burnet Institute to commercialise research outcomes in the areas of diagnosis, vaccination and therapy for infectious diseases caused by viruses.

The Burnet Institute, established in 1986, is Australia's leading research organisation in the field of infectious diseases caused by viruses and other agents.

Select has formed two project companies, Hepgenics Pty Ltd and Picoral Pty Ltd, to undertake different areas of research and development. Hepgenics is commercialising highly promising R&D projects in hepatitis diagnostics and vaccines developed by researchers at the Burnet Institute. Picoral's research interests cover the development of therapeutic products with actions against the picornavirus family, responsible for a range of illnesses that includes the common cold, meningitis and encephalitis.

ENDS

Further information Select Vaccines:

Dr Martin Soust, Managing Director

(03) 8508 8250

Mobile: 0412 442 844

Select Vaccines Limited
ABN 25 062 063 692

PO Box 46 Armadale
Victoria 3143 Australia
Telephone +613 9824 8166
Facsimile +613 9824 8161

www.selectvaccines.com.au